Kiang Wu Hospital

Everest Medicines announced the NMPA of China accepted the NDA for VELSIPITY(R) (etrasimod) for treating moderately to severely active ulcerative colitis. VELSIPITY(R), a once-daily oral treatment, has been approved in Macau and Singapore, aiming to benefit more patients in China by 2030.

Everest Medicines announced NMPA accepted VELSIPITY® (etrasimod) NDA for UC treatment. VELSIPITY®, a once-daily oral S1P receptor modulator, is effective for moderately to severely active UC. It was approved in Macau and Singapore, with mainland China potentially being the third approval. Everest aims to expand access to VELSIPITY® to benefit more UC patients in China, where the UC patient population is expected to double by 2030.

Everest Medicines announced the first prescription of VELSIPITY® (etrasimod) in Macau, marking the start of its availability in Asia. VELSIPITY®, an oral S1P receptor modulator, was approved in Macau in April 2024 for treating moderately to severely active ulcerative colitis. The drug has shown positive results in Asian Phase III clinical trials and is expected to be submitted for approval in mainland China by the end of 2024.